Consists of diclofenac sodium, paracetamol
Actions of Diclofenac sodium (Inflaryl-AD) in details
Diclofenac sodium (Inflaryl-AD) sodium extended-release tablets have analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of Diclofenac sodium (Inflaryl-AD) sodium extended-release tablets, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2). Diclofenac sodium (Inflaryl-AD) is a potent inhibitor of prostaglandin synthesis in vitro. Diclofenac sodium (Inflaryl-AD) concentrations reached during therapy have produced in vivo effects. Prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain in animal models. Prostaglandins are mediators of inflammation. Because Diclofenac sodium (Inflaryl-AD) is an inhibitor of prostaglandin synthesis, its mode of action may be due to a decrease of prostaglandins in peripheral tissues.
How should I take Diclofenac sodium (Inflaryl-AD)?
Take Diclofenac sodium (Inflaryl-AD) exactly as directed on the label, or as prescribed by your doctor. Your doctor may occasionally change your dose to make sure you get the best results. Do not take this medicine in larger amounts or for longer than recommended. Use the lowest dose that is effective in treating your condition.
For treatment of pain or primary dysmenorrhea the recommended dosage of Diclofenac sodium (Inflaryl-AD) is 50 mg three times daily. In some patients an initial dose of 100 mg of Diclofenac sodium (Inflaryl-AD), followed by 50 mg doses, may provide better relief.
For the relief of osteoarthritis the recommended dosage of Diclofenac sodium (Inflaryl-AD) is 100-150 mg/day in divided doses, i.e. 50 mg two or three times a day.
For the relief of rheumatoid arthritis the recommended dosage is 150-200 mg/day in divided doses, i.e. 50 mg three or four times a day.
Different formulations of Diclofenac sodium (Inflaryl-AD), Voltaren (Diclofenac sodium (Inflaryl-AD) sodium tablets) and Diclofenac sodium (Inflaryl-AD) (Diclofenac sodium (Inflaryl-AD) potassium immediate-release tablets) are not necessarily equivalent in strength even if the milligram strength is the same.
If you use Diclofenac sodium (Inflaryl-AD) long-term, you may need frequent medical tests.
Store at room temperature away from moisture and heat. Keep the bottle tightly closed when not in use.
Read all patient information, medication guides, and instruction sheets provided to you. Ask your doctor or pharmacist if you have any questions.
Diclofenac sodium (Inflaryl-AD) administration
Take exactly as prescribed by your doctor. Do not take in larger or smaller amounts or for longer than recommended. Follow the directions on your prescription label.
If you switch brands of Diclofenac sodium (Inflaryl-AD), your dose needs may change. Follow your doctor's instructions about how much medicine to take.
Do not crush, chew, or break an extended-release tablet. Swallow it whole. Breaking the pill may cause too much of the drug to be released at one time.
Dissolve the Diclofenac sodium (Inflaryl-AD) powder (Diclofenac sodium (Inflaryl-AD)) with 1 to 2 ounces of water. Do not use any other type of liquid. Stir this mixture and drink all of it right away. Diclofenac sodium (Inflaryl-AD) powder works best if you take it on an empty stomach.
Call your doctor if your headache does not completely go away after taking Diclofenac sodium (Inflaryl-AD). Do not take a second dose of Diclofenac sodium (Inflaryl-AD) powder without your doctor's advice.
Do not crush, chew, or break an enteric-coated pill. Swallow the pill whole. The enteric-coated pill has a special coating to protect your stomach. Breaking the pill could damage this coating.
If you use this medication long-term, your liver function will need to be checked with frequent blood tests. Visit your doctor regularly.
Store at room temperature away from moisture and heat.
Diclofenac sodium (Inflaryl-AD) pharmacology
Pharmacodynamics
Diclofenac sodium (Inflaryl-AD) sodium is one of a series of phenylacetic acids that has demonstrated anti-inflammatory and analgesic properties in pharmacological studies. It is thought to inhibit the enzyme cyclooxygenase, which is essential in the biosynthesis of prostaglandins.
Animal Studies
Prostaglandins have been shown in many animal models to be mediators of certain kinds of intraocular inflammation. In studies performed in animal eyes, prostaglandins have been shown to produce disruption of the blood-aqueous humor barrier, vasodilation, increased vascular permeability, leukocytosis, and increased intraocular pressure.
Pharmacokinetics
Results from a bioavailability study established that plasma levels of Diclofenac sodium (Inflaryl-AD) following ocular instillation of two drops of Diclofenac sodium (Inflaryl-AD) sodium ophthalmic solution, 0.1% to each eye were below the limit of quantification (10 ng/mL) over a 4-hour period. This study suggests that limited, if any, systemic absorption occurs with Diclofenac sodium (Inflaryl-AD) sodium ophthalmic solution, 0.1%.
Clinical Trials
Postoperative Anti-Inflammatory Effects
In two double-masked, controlled, efficacy studies of postoperative inflammation, a total of 206 cataract patients were treated with Diclofenac sodium (Inflaryl-AD) sodium ophthalmic solution, 0.1% and 103 patients were treated with vehicle placebo. Diclofenac sodium (Inflaryl-AD) sodium ophthalmic solution, 0.1% was favored over vehicle placebo over a 2-week period for the clinical assessments of inflammation as measured by anterior chamber cells and flare.
In double-masked, controlled studies of corneal refractive surgery (radial keratotomy (RK) and laser photorefractive keratectomy (PRK)) patients were treated with Diclofenac sodium (Inflaryl-AD) sodium ophthalmic solution, 0.1% and/or vehicle placebo. The efficacy of Diclofenac sodium (Inflaryl-AD) sodium ophthalmic solution, 0.1% given before and shortly after surgery was favored over vehicle placebo during the 6-hour period following surgery for the clinical assessments of pain and photophobia. Patients were permitted to use a hydrogel soft contact lens with Diclofenac sodium (Inflaryl-AD) sodium ophthalmic solution, 0.1% for up to three days after PRK.
Actions of Paracetamol (Inflaryl-AD) in details
Pharmacology: Paracetamol (Inflaryl-AD) exhibits analgesic and antipyretic activity by inhibiting prostaglandin synthesis. It produces analgesia by elevating the pain threshold and antipyresis through action on the hypothalamic heat-regulating center.
In therapeutic doses, Paracetamol (Inflaryl-AD)'s analgesic and antipyretic action is comparable to that of aspirin. Paracetamol (Inflaryl-AD) does not adversely affect platelet function and hemostasis.
Pharmacokinetics: Paracetamol (Inflaryl-AD) is rapidly and completely absorbed after oral administration. Peak plasma concentrations occur between 15 min to 2 hrs after ingestion. The absolute oral bioavailability of Paracetamol (Inflaryl-AD) is about 80% and is independent of dose in the range of 5-20 mg/kg.
Paracetamol (Inflaryl-AD) is not bound to plasma proteins to any extent. The concentrations of Paracetamol (Inflaryl-AD) in saliva are similar to those in plasma. Concentrations in whole blood are up to 20% higher and in breast milk about 20% lower than the plasma concentration. Paracetamol (Inflaryl-AD) crosses the placenta.
Paracetamol (Inflaryl-AD) is extensively metabolized in the liver and the total body clearance is about 5 mL/kg/min. The clearance of Paracetamol (Inflaryl-AD) is reduced and the half-life increased following a hepatotoxic overdose. Prolongation of half-life beyond 4 hrs usually indicates impending liver damage.
Two to five percent of a therapeutic dose of Paracetamol (Inflaryl-AD) is excreted unchanged in the urine. Its renal clearance is about 10 mL/min and is weakly dependent on urine flow rate but not on pH.
Paracetamol (Inflaryl-AD) administration
May be taken with or without food.
Paracetamol (Inflaryl-AD) pharmacology
The analgesic, antipyretic, and anti-inflammatory effects of aspirin are due to actions by both the acetyl and the salicylate portions of the intact molecule as well as by the active salicylate metabolite. Paracetamol (Inflaryl-AD) directly and irreversibly inhibits the activity of both types of cyclo-oxygenase (COX-1 and COX-2) to decrease the formation of precursors of prostaglandins and thromboxanes from arachidonic acid. This makes aspirin different from other NSAIDS (such as Paracetamol (Inflaryl-AD) and ibuprofen) which are reversible inhibitors. Salicylate may competitively inhibit prostaglandin formation. Paracetamol (Inflaryl-AD)'s antirheumatic (nonsteroidal anti-inflammatory) actions are a result of its analgesic and anti-inflammatory mechanisms; the therapeutic effects are not due to pituitary-adrenal stimulation. The platelet aggregation–inhibiting effect of aspirin specifically involves the compound's ability to act as an acetyl donor to the platelet membrane; the nonacetylated salicylates have no clinically significant effect on platelet aggregation. Paracetamol (Inflaryl-AD) affects platelet function by inhibiting the enzyme prostaglandin cyclooxygenase in platelets, thereby preventing the formation of the aggregating agent thromboxane A2. This action is irreversible; the effects persist for the life of the platelets exposed. Paracetamol (Inflaryl-AD) may also inhibit formation of the platelet aggregation inhibitor prostacyclin (prostaglandin I2) in blood vessels; however, this action is reversible.
References
- DailyMed. "DICLOFENAC EPOLAMINE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- NCIt. "Diclofenac: NCI Thesaurus (NCIt) provides reference terminology for many systems. It covers vocabulary for clinical care, translational and basic research, and public information and administrative activities.". https://ncit.nci.nih.gov/ncitbrowser... (accessed September 17, 2018).
- EPA DSStox. "Diclofenac: DSSTox provides a high quality public chemistry resource for supporting improved predictive toxicology.". https://comptox.epa.gov/dashboard/ds... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Inflaryl-AD are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Inflaryl-AD. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported administration
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
